Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
h6mjw1S4Rj3tdqzw